Background: Subclinical hypothyroidism itself is associated with serious complications and also there is a known risk of subclinical hypothyroidism patients getting converted into overt disease. Objectives: The objective of the present study was to fi nd out the prevalence of subclinical hypothyroidism in the suspected cases i.e. amongst the cases attending the thyroid laboratory at B.P. Koirala Institute of Health Sciences, Dharan, Nepal. Materials and methods: It was a retrospective cross sectional study. Data of the free T 3 , free T 4 and TSH estimations of the year 2007 of the Thyroid lab at BPKIHS, Dharan, Nepal was analyzed. ELISA based free T 3 , free T 4 and TSH tests in the serum had been performed in all the cases. Results: Total cases were 1714 including 24.446% males and 75.554% females. Cases with raised TSH levels were 26.021%, cases with normal TSH levels were 54.66% and cases with low TSH levels were 19.316%. Total 350 cases (20.42 %) had subclinical hypothyroid dysfunction which includes 84 (4.901 %) males and 266 (15.519%) females. And the maximum percentage of cases in either gender was between the age groups 20 -59 years.
T hyroid dysfunction is a major public health problem among the local population in Eastern Nepal 1 . Hypothyroidism results from inadequate production of thyroid hormone, and is classifi ed as clinical or subclinical depending on the degree of clinical severity and the extent of abnormalities in thyroid indices. Subclinical hypothyroidism (SH) is defi ned as the clinical status of elevated serum TSH levels with normal levels of serum thyroxine (T 4 ) and triiodothyronine (T 3 ) and is a more common disorder than overt hypothyroidism with a prevalence of 1.4-7.8% in older populations and even greater percentiles among women 2 . SH is most commonly an early stage of hypothyroidism and is associated with few or no symptoms of hypothyroidism. The condition may resolve or remain unchanged, or may progress to overt hypothyroidism in a few years in some patients. SH holds a special importance as not only SH itself is associated with serious complications, but also, due to known risk of SH patients getting converted into overt disease which is approximately 5% per year 3, 4 . In the management of such cases there are two crucial points which still continue to be controversial issues, the fi rst is whether to go for a population screening for SH and the second is whether to treat SH or not. The available evidence is not suffi cient to recommend for or against the screening or treatment of SH, despite a welldocumented list of associated symptoms.
Today, it is accepted that most SH, like most overt hypothyroidism, is caused by autoimmune thyroid disease. Subclinical hypothyroidism also occurs in patients with infectious, silent, or postpartum thyroiditis, patients on excessive doses of anti-thyroid medications, lithium and other medications, patients with hypothyroidism who are on inadequate doses of replacement hormone, and patients with diminished thyroid function related to permanent treatment for hyperthyroidism 5 . Subclinical hypothyroidism (SH) is a common disorder with a prevalence of 4 -8.5% in the adult population in most community studies globally ranging from even as low as 1% to as high as 10% in some studies and the risk of developing SH increases with female gender and advanced age 2, 6 -18 .
The available evidence is not suffi cient to recommend for or against the routine screening or treatment of SH. Although the condition may resolve or remain unchanged, within a few years in some patients, overt hypothyroidism develops, with low thyroid hormones levels along with a raised TSH level. The likelihood that this will happen increases with greater TSH elevations and detectable antithyroid antibodies. Because patients with subclinical hypothyroidism sometimes have subtle hypothyroid symptoms and may have mild abnormalities of serum lipoproteins and cardiac function, patients with defi nite and persistent TSH elevation should be considered for thyroid treatment. Levothyroxine, in a dosage that maintains serum TSH levels within the normal range, is the preferred therapy in these patients 5 . Unfortunately, treatment is often withheld in SH despite a well-documented list of associated symptoms. These include most commonly elevated lipid levels and others including cardiac abnormalities, congestive heart failure, latency of motor nerve conduction, increased intraocular pressure, arthralgia, depression and cognitive changes. A recent study by Walsh, et al 19 . confi rmed that subclinical hypothyroidism, but not subclinical hyperthyroidism, is associated with an increase in fatal and nonfatal coronary heart disease. SH, women older than 50 years of age with markedly elevated TSH levels (>10 mIU/L) have the highest risk for complications. SH is known to be associated with dyslipidemia leading to increased risk of atherosclerosis. Some studies have indicated that SH is with increased risk of CAD, especially in women with antibodies to thyroid peroxidase as well as in smokers, the SH-induced lipid abnormalities offering the most obvious explanation for this association 17, 20 . Moreover, SH impairs ventricular function as well as cardiovascular and respiratory adaptation to effort 20 . Although it is clear that thyroid replacement therapy has benefi cial effects on the serum lipid profi le and on the risk of CAD in patients with overt hypothyroidism, the question of whether SH should be treated or not remains unanswered 21 .
Several studies have shown that a modest fraction of patients with subclinical hypothyroidism (approximately 3 to 5% per year, depending on age and magnitude of TSH elevation) within a few years have progression to overt hypothyroidism with a decline in serum free thyroxine concentration 3, 4 . Approximately 18% of elderly patients with elevated TSH but normal FT 4 will develop low FT 4 when followed for 12 months 10 . The hypothyroidism complications are known to have serious consequences e.g. in children it may lead to mental retardation, deafness and ataxia, lower IQ, delayed sexual maturation and the onset of puberty etc. Hypothyroidism during fetal/post-natal life interferes with the normal development of CNS and increases infant mortality, congenital abnormalities, stunted growth and dwarfi sm and is associated with a waddling gait, etc. In adults the hypothyroidism may be responsible for reduced fertility, impaired mental function, CHD and atherosclerosis, anaemia, pleural effusion, reduced appetite, constipation, delayed muscle contraction and relaxation, decreased renal blood fl ow and glomerular fi ltration rate, etc. In pregnant women hypothyroidism leads to abortion and premature delivery, still birth or birth of congenitally defective babies. Considering the above potential dangers of hypothyroidism, there needs to be proper guidelines to recommend the screening and treatment of SH if not in a general population, at least in a selected population as there is a potential danger to progression to overt disease state.
Recommendations about thyroid screening, however, have been inconsistent. American Thyroid Association recommends that adults be screened for thyroid dysfunction by measurement of the serum thyrotropin concentration, beginning at age 35 years and every 5 years thereafter particularly in women. Individuals with symptoms and signs potentially attributable to thyroid dysfunction and those with risk factors for its development may require more frequent serum thyrotropin testing. According to American College of Physicians, and American Academy of Family Physicians, there is insuffi cient evidence to recommend routine screening 5 . The U.S. Preventive Services Task Force concludes the evidence is insuffi cient to recommend for or against routine screening for thyroid disease in adults 22 . And some authors 23 have recommended testing in women more than 40 years of age and in geriatric patients. Danese and co-workers 24 demonstrated through a decision model that TSH screening every fi ve years, starting at age 35, was costeffective because progression to overt hypothyroidism was prevented, serum cholesterol levels were reduced and symptoms were relieved with early treatment of hypothyroidism. The American Thyroid Association recommends that adults be screened for thyroid dysfunction by measurement of the serum thyrotropin concentration, beginning at age 35 years and every 5 years thereafter 25 . 
Materials and methods

Discussion
The objective of the present study was to fi nd out the prevalence of subclinical hypothyroidism in the suspected cases i.e. amongst the cases attending the thyroid lab at B.P. Koirala Institute of Health Sciences, Dharan, Nepal. In the present study, the total number of patients with raised TSH levels which includes SH and overt hypothyroidism were 446 which including 103 males and 343 females. Among the 103 males with raised TSH, 84 males or 81.5 % had SH and only 19 or 18.45 % had full blown overt hypothyroid state. Among the 343 females with raised TSH, 266 (77.55%) females had SH and 77 (22.45 %) had full blown overt hypothyroid state. Thus total 350 (20.42% of total 1714 cases) had subclinical hypothyroid dysfunction including 84 males and 266 females. The prevalence of SH in the suspected male cases was 4.901 % and in the suspected female cases was 15.519 % and the overall prevalence in the suspected cases taken together thus was 20.42% which is much higher as compared to the prevalence found in the other epidemiological studies in the other parts of the world which ranges from as low as 1% to an average of 4 -8.5 % 2, 6 -18 . The results of the present study though much higher but are in agreement with the data across the world in terms of high prevalence of SH among females. As there was an overall much higher percentage of female subjects (75.554%) compared to males (24.446%) consequently the number of female subjects was much higher in both high TSH and SH groups compared to males as shown in the table-4. Age-sex wise distribution of SH cases (Table-5 ) has demonstrated that 77.38 % of males and 86.09 % of females were between the age groups 20 -59 years which is slightly higher as compared to the overall distribution of cases with males 76.2% and females 82.9% in the age groups 20 -59 years (Table-1 ). The highest percentage of SH cases was thus found in the female age group 20 -59 years.
As this is a hospital based study so naturally the positive cases are expected more but it gives an idea about the high incidence rates in the society as well but for getting a clear picture an extensive epidemiological study is required. In one of the study conducted at BPKIHS in 2002, a total of 599 cases were studied during a single year and the cases with raised TSH were 17.19% with slightly higher prevalence among terai castes (17.66%) when compared with hill castes (15.17%).
1 But till date no detailed study in this region is available for subclinical hypothyroidism though there are a few studies available on iodine defi ciency disorders in Nepal and one of the study showed a decline in the prevalences of iodine defi ciency disorders among Sherpa residents of the Khumbu region of Nepal but still iodine defi ciency continued to be a major problem in Khumbu and demanded a clear control strategy, combining ongoing iodine supplementation and education 26 .
At this juncture, evidence does not support the routine universal screening for SH or recommend for the treatment of SH 5, 21, 22 . The routine universal screening for SH is not cost effective especially in the developing countries but considering the potential known danger of SH itself being associated with serious complications especially in females above 50 years 17, 20 and also due to a known risk of substantial number of SH patients getting converted into overt disease 3, 4 , we feel that some strategy should be formalised for the screening of SH and the undertaken study provides support for the screening in selected populations. The American Thyroid Association recommends that adults be screened for thyroid dysfunction by measurement of the serum thyrotropin concentration, beginning at age 35 years and every 5 years thereafter 25 . But considering a higher percentage of cases in the female reproductive age groups in Eastern Nepal found in the present study especially in the younger 20 to 39 years age groups and also taking into consideration the potential danger of hypothyroidism to the pregnant women and the developing foetus we recommend the screening to be started as early as 20 years and every 5 years thereafter rather than 35 years as advised by the American Thyroid Association. The two recommended methods for thyroid hormonal assays are RIA and ELISA for their high sensitivity and specifi city. Because for the known drawbacks with RIA as it is not only very costly to perform but also there is potential danger of radioactivity hazards, special training to the lab personnel is required and special precautions need to be taken. On the other hand ELISA technique is not only cost effective and easy to perform but is also equally highly sensitive and specifi c. Especially in a country like Nepal where cost effectiveness is an essential requirement ELISA technique is recommended by us for not only for TSH but also for other hormonal assays. The preferred screening method advised is a sensitive ELISA based TSH test. But further work is needed to establish the optimum strategy for screening. As it was a hospital based study, the results may not be applicable to the general population as follow up patients from the previous years or from other centres cannot be ruled out despite taking precautions to exclude such patients. Therefore it is suggested that an extensive epidemiological studies should be carried out.
Conclusion
A higher prevalence of SH was expected as thyroid dysfunction is a major public health problem among the local population in Eastern Nepal 1 but exact prevalence was not known and this is the fi rst study in this direction. The study revealed percentage of subclinical hypothyroidism among the patients referred to thyroid lab at B.P.K.I.H.S. in Eastern Nepal is 20.42 % representing the prevalence amongst the suspected cases which is quite high as compared to the prevalence found in the other epidemiological studies in the other parts of the world which ranges from as low as 1% to an average of 4 -8.5 %. The highest percentage of SH cases was found especially in the female age group 20 -59 years. Considering the potential danger to progression to overt disease state and also SH may itself associated with serious complications, there needs to be proper guidelines to recommend the screening and treatment of SH. As the routine screening of the whole population is not cost effective thus on the basis of the present study it is suggested that there may be routine screening of the selected populations, especially women between 20 to 59 years of age in Nepal region, starting at the age of 20 years and every 5 years thereafter. The preferred screening method advised is a sensitive ELISA based TSH test. As it was a hospital based study, further epidemiological studies are required.
